UK government's consultation on value-based pricing for pharmaceuticals imminent
This article was originally published in SRA
Executive Summary
The Department of Health in the UK will this week launch for consultation its plans for value-based pricing for pharmaceuticals, it has told Regulatory Affairs Pharma's sister publication Scrip Intelligence. The consultation will touch on the government's plans for the National Institute for Clinical Excellence, which will see the health technology assessment body cede to GPs (primary care physicians) its authority to definitively recommend whether or not to make certain drugs available on the National Health Service in England and Wales.